ClinicalTrials.gg
Not yet recruitingNCT07126041SPHERESUpdated Aug 15, 2025

Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)

An interventional study of Prescription for Action (SPHERES Model) in Pregnancy, Neonatal Mortality and Tuberculosis, sponsored by Oxford University Clinical Research Unit Indonesia. Not yet recruiting at 2 sites in Indonesia. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Oxford University Clinical Research Unit Indonesia · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,750,000
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Tuberculosis with a site in Indonesia — 8 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis · Indonesia.

Planned enrollment
Largest of 35
1,750,000 · median 78
Started
2025
with 4 others
No phase
18 of 38
3 open now
Primary completion
2026-12
later than 7 of 12 live
Registered
30th of 38
by date

Among the 38 studies in Tuberculosis with a site in Indonesia, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2025, is one of 18 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 30th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

8 of the 38 studies in Tuberculosis with a site in Indonesia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Tuberculosis with a site in Indonesia, or all of them as a file.
02

Study summary

SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs.

Read the detailed description

The SPHERES (Scalable Public Health Empowerment, Research and Education Sites) study is a stepped-wedge health service research trial designed to assess the impact of a complex intervention to enhance the performance of Indonesia's primary health care system through an integrated package of digital health tools to enhance data interoperability, human resource and performance improvement, data-driven decision-making, and changes in work culture toward information-based decision-making, actions, and accountability. The central innovation lies in the "prescription for action" approach, wherein district health managers and heads of primary healthcare centers (PHC) create structured monthly prescriptions that describe actions to be taken to improve primary health care informed by real-time health data visualized on interactive dashboards. These prescriptions are tailored to address gap in priority service delivery challenges including gaps in preventive and promotive care - such as low coverage or quality of antenatal, intrapartum, or postnatal care, or missed opportunities for hepatitis B prevention in pregnancy, or gaps in overall diagnosis and treatment of tuberculosis, or gaps in overall screening and diagnosis and treatment of hypertension or diabetes, - and are grounded in both epidemiological insight and health systems analysis.

As a cluster-randomized stepped-wedge health service trial in the Indonesian primary care system, SPHERES involve multiple primary healthcare centers (PHCs) as the unit of intervention across two districts: West Lombok (West Nusa Tenggara Province) and Purbalingga (Central Java Province). At regular intervals (approximately every 4 months), new clusters (approximately 25% of the total number of PHCs in the district) are transitioned from control to intervention status, until all sites receive the SPHERES intervention within 16 months. This phased approach allows for rigorous evaluation while ensuring equitable access to the program. The intervention package includes: (1) establishment of Public Health Data Theaters as training centers for the active use of data for decision-making using interactive dynamic dashboards, public health data rounds, prescriptions for action for precision public health, digital report cards, and team-based care, (2) deployment of Sustainable Scaling Teams to engage districts in developing the essential technical and management skills for digital ecosystems, and (3) establish ecosystems of interoperable data at the district level to support curative, preventive, and promotive care delivery by frontline health workers. Thus, the intervention will be implemented over 16 months, with approximately 25% of PHCs transitioning every quarter from control to intervention in monthly waves, starting August 2025, with all PHCs receiving the intervention by August 2026.

To support high-fidelity implementation, at each phase of the stepped-wedge, each cluster undergoes a two-phase transformation, a pre-intervention digital readiness phase, followed by the intervention interventions, i.e. the "prescriptions for action" phase. The preparatory step focuses on strengthening digital infrastructure and practices at the PHC level, including standardizing electronic health record inputs, and ensuring interoperability across digital health platforms. Sequencing this digitalization phase ahead of the "prescriptions for action" phase enhances the fidelity and compliance for managerial and behavioral actions that may be included within the "prescriptions for action" intervention.

SPHERES targets improvements in coverage, quality, and outcomes across three priority domains: maternal and child health (including immunization and stunting), infectious disease (tuberculosis and hepatitis B), and non-communicable diseases (diabetes and hypertension). The study will assess impacts on service uptake (e.g., ANC 6 coverage, quality of care, diabetes screening), clinical outcomes (e.g., neonatal mortality, TB treatment success, Hepatitis B vertical transmission), and system-level indicators (e.g., prescription compliance, data use in decision-making). Embedded within the project is a robust capacity-building component for health workers and program managers, along with qualitative assessments of acceptability, feasibility, and perceived value.

SPHERES is expected to produce evidence for improving PHC service quality and responsiveness across Indonesia. By combining routine data analytics with a structured decision-support mechanism, the intervention aims to institutionalize active data use at the district level. Findings from SPHERES are expected to inform Indonesia's Ministry of Health Digital Roadmap and broader digital health transformation strategy and offer generalizable insights into how data empowerment combined with human resource management and change in work culture can drive system-wide improvements in low- and middle-income countries.

03

Conditions studied

  • Pregnancy
  • Neonatal Mortality
  • Tuberculosis
  • Hepatitis B
  • Hypertension
  • Diabetes Mellitus

Keywords

  • Primary health care performance
  • Digital health transformation
  • Maternal health
  • Child health
  • Immunization
  • Stunting
  • Tuberculosis
  • Hepatitis B
  • Diabetes mellitus
  • Hypertension
  • Health system strengthening
  • Indonesia
  • Health governance
  • Human resource management
  • Work culture
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residing in or participating in the district catchment areas
  • Receiving services from participating health care facilities
  • Health providers and district health officials consent to participate in data collection

Exclusion criteria

Exclusion Criteria:

  • Individuals (health workers or patients) who decline to provide .
  • Individuals who are not directly involved in or accessing services from health care facilities or district health offices.
  • Inability to provide consent due to cognitive impairment or acute illness for health workers or district health officials involved in data collection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,750,000 participants (estimated)

Study arms

  • Experimental
    SPHERES Intervention Arm

    Participants (district populations) receive services improved by the SPHERES model, which includes structured prescription-for-action protocols targeting three priority domains (infectious disease, maternal \& child health, and non-communicable diseases).

    Other: Prescription for Action (SPHERES Model)

  • No intervention
    Control

    Standard of care are expected at primary health centers before the SPHERES intervention is deployed

Interventions

  • OtherPrescription for Action (SPHERES Model)

    A system-level intervention consisting of: * a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater; * structured monthly prescription guides targeting service improvements across three priority program areas; * monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange.

06

What researchers measure

Primary outcomes

  1. Difference in neonatal mortality rate between intervention and control periods

    Neonatal mortality per 1,000 live births, calculated using health facility and civil registration data, and community household sampling surveys

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

Secondary outcomes

  1. Difference in complete antenatal care (ANC 6) visit coverage between intervention and control periods

    Percentage of pregnant women completing ≥6 ANC visits calculated using health facility data, paper based registry, and/or community household sampling surveys

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  2. Difference in complete basic childhood immunization coverage between the intervention and control period

    Proportion of children aged 12-23 months receiving all recommended basic childhood vaccines according to Indonesian Pediatric Society guidelines using health facility data, paper based registry, and/or community household sampling surveys

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  3. Difference in TB treatment success rate between intervention and control periods

    Percentage of new bacteriologically confirmed TB patients with documented treatment success (cure or completion) calculated using health facility data

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  4. Difference in screening coverage for diabetes mellitus among adults between the intervention and control periods

    Proportion of adults aged ≥40 screened for random blood glucose or fasting blood glucose calculated using health facility data

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  5. Difference in the rate of vertical transmission of hepatitis B between intervention and control periods

    Proportion of infants born to hepatitis B surface antigen (HBsAg)-positive mothers who test positive for HBsAg at 9 to 12 months of age. Data will be collected to evaluate the effectiveness of Tenofovir initiation, timely birth dose, routine childhood Hepatitis B vaccination, and HBIG administration as part of the vertical transmission prevention protocol.

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  6. Difference in the uptake of dashboard use among district health managers and heads of PHC

    Proportion of monthly coordination meetings in which district health managers and heads of PHC accessed and used the SPHERES digital dashboard to review performance data and guide decision-making. Usage will be measured through system access logs and meeting documentation.

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

  7. Difference in prescription-for-action implementation rate at the PHC

    Proportion of prescriptions-for-action issued during Public Health Data Theater sessions that are completed by PHCs within one month. Data will be collected from district monitoring reports and PHC-level follow-up documentation.

    Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)

07

Study locations

2 sites
  • Purbalingga District Health Office
    Purbalingga, Central Java, Indonesia
    • Jusi Febrianto, MD, MPH · Contactrbdpn2001@yahoo.co.id · +628156704738
    • Jusi Febrianto, MD, MPH · Principal investigator
  • West Lombok District Health Office
    Gerung, West Nusa Tenggara, Indonesia
08

References and documents

Individual participant data

Plan to share: No — The study will not share individual participant data due to the population-level nature of the intervention and national data privacy regulations. Only aggregated and de-identified/anonymized data and codebook may be made publicly available upon publication. All data collection, storage, and analysis procedures will comply with Indonesia's Personal Data Protection Law (UU PDP), Ministry of Health guidance, and institutional ethical standards.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

Of 169 non-industry interventional studies with no phase under Tuberculosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 16 months is below that.

Counting every sponsor, half of 171 studies reached it within 25 months; a quarter within 14 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 15, 2025
StartEst.
Aug 14, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07126041
Lead sponsor
Oxford University Clinical Research Unit Indonesia
Collaborators
Summit Institute for Development, Indonesia
Responsible party
Anuraj Shankar (D. Sc., Oxford University Clinical Research Unit Indonesia) — Principal investigator
First posted
Aug 15, 2025
Start date
Aug 14, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 15, 2025

Study contacts

Zamzam Noerzen Djaelani, MD, MBA
Contact
zdjaelani@oucru.org
+6281385680388
Rina Agustina, Prof.
Contact
ragustina@oucru.org
+6281297484775
Anuraj H Shankar, D. Sc.
principal investigator · Oxford University Clinical Research Unit Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion